Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-05
2006-09-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S072000
Reexamination Certificate
active
07101890
ABSTRACT:
New derivatives of benzazepine, particularly of benzofuro[3a,3,2,ef][2]benzazepin of the general formula (I)and new compounds of the general formula (III)Drugs, containing compounds of formulas (I) and/or (III), which can be used successfully for the treatment of Alzheimer's disease and related dementia conditions, as well as for the treatment of Langdon-Down syndrome, are also described.
REFERENCES:
patent: 3947445 (1976-03-01), Henry et al.
patent: 5153193 (1992-10-01), Flanagan et al.
patent: 5336675 (1994-08-01), Snorrason
patent: 5428159 (1995-06-01), Shieh et al.
patent: 6043359 (2000-03-01), Czollner et al.
patent: 6369238 (2002-04-01), Czollner et al.
patent: 6407229 (2002-06-01), Czollner et al.
patent: 6638925 (2003-10-01), Czollner et al.
patent: 401 058 (1996-06-01), None
patent: 0 236 684 (1987-09-01), None
patent: 0 345 808 (1989-12-01), None
patent: 648 771 (1995-04-01), None
patent: 0 653 427 (1995-05-01), None
patent: 8800350 (1989-09-01), None
patent: WO 88/08708 (1988-11-01), None
patent: WO 95/27715 (1995-10-01), None
patent: WO 96/12692 (1996-05-01), None
patent: WO 97/11078 (1997-03-01), None
patent: WO 00/32199 (2000-06-01), None
patent: WO 2005/030333 (2005-04-01), None
P. Remuzon, “Fluoronaphthyridines as Antibacterial Agents.”, J. Med. Chem., 1992, vol. 35, pp. 2898-2909.
Bastida et al., “Narcissus Alkaloids. Part 19. Alkaloids from Narcissus Leonensis,” Phytochemistry, 3496): 1656-1658, XP001009775 (1993).
Pilger et al., “Accurate Prediction of the Bound Conformation of Galanthamine in the Active Site of Torpedo Californica Acetylcholinesterase Using Molecular Docking,”J. Molecular Graphics and Modeling, 19:288-296 (2001).
Pokorna et al., “Capillary Zone Electrophoresis Determination of Galanthamine in Biological Fluids and Pharmaceutical Preparatives: Experimental Design and Artificial Neural Network Optimization,”Electrophoresis, 199, 20, 1993-1997.
Poschalko et al., “Synthesis of (+)-6H-benzofuro[3a, 3, 2, ef][ 3]benzazepine: an unnatural analog of (−)galanthamine,”Tetrahedron, 58: 1513-1518 (2002).
Roques et al., “Structure of Norgalanthamine Hydrochloride, ”ACTA GRYSTALLOGR, Sect. B, B36(7): 1589-1593, XP001009771 (1980).
U.S. Appl. No. 2003/0199493 A1, Oct. 23, 2003, Jordis et al.
Czollner Laszlo
Frohlich Johannes
Jordis Ulrich
Kuenburg Bernhard
Kifle Bruck
Popovich, Wiles & O'Connell , P.A.
Sanochemia Ltd.
LandOfFree
Benzazepine derivatives, drugs containing these and use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzazepine derivatives, drugs containing these and use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzazepine derivatives, drugs containing these and use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3569256